Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 9/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063265 | 1.00 | CLK1 (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4062708 | 0.96 | CLK1 (0.93) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| Acetic Acid SCHEMBL4066978 | 0.95 | CLK1 (0.91) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4795234 | 0.92 | CLK1 (0.85) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066988 | 0.87 | HTT (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL14863869 | 0.87 | CLK1 (0.77) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4071064 | 0.85 | HTT (0.81) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066980 | 0.85 | CLK1 (0.73) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4065608 | 0.85 | HTT (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066650 | 0.82 | CLK1 (0.70) | CLK1GSK3BDYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | disclosed |
| CN-117243977-A | Application of isoxazole-9 combined mesenchymal stem cells in preparation of medicines for preventing or treating acute lung injury | 上海交通大学医学院附属瑞金医院 | 2023-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | CLK1 1305/4885GSK3B 2729/4885DYRK1A 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.